Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer

Qi,Qiufeng; Ling,Yang; Zhu,Ming; Zhou,Linyan; Wan,Meizhen; Bao,Yanqing; Liu,Yongping

doi:10.3892/br.2014.298

Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer

Authors:
- Qiufeng Qi
- Yang Ling
- Ming Zhu
- Linyan Zhou
- Meizhen Wan
- Yanqing Bao
- Yongping Liu
View Affiliations

Affiliations: Clinical Oncology Laboratory Departments, Changzhou Tumor Hospital Affiliated to Suzhou University, Changzhou, Jiangsu 213002, P.R. China, Department of Oncology, Changzhou Tumor Hospital Affiliated to Suzhou University, Changzhou, Jiangsu 213002, P.R. China, Department of Pathology, Changzhou Tumor Hospital Affiliated to Suzhou University, Changzhou, Jiangsu 213002, P.R. China
Published online on: June 16, 2014 https://doi.org/10.3892/br.2014.298
Pages: 653-658

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The genetic basis underlying cervical tumorigenesis and progression are largely unknown. Phosphatase and tensin homologue (PTEN) is a tumor suppressor gene, and genetic changes of PTEN occurs in various types of cancer suggesting that the inactivation of PTEN may play an important role in the pathogenesis of a variety of human malignancies. In the present study, 102 cervical cancer specimens were examined for the expression of the PTEN gene and promoter methylation using methylation‑specific‑polymerase chain reaction and immunohistochemistry. The PTEN gene mutation was also assessed using PCR single‑strand conformational polymorphism. We examined the correlation between PTEN expression and its associated methylation status and the clinical characteristics of cervical cancer. The results showed that there was one case of an A to G point mutation on exon 9 of the PTEN gene in the cervical cancer tissues. This mutation caused the change of aspartic acid to glycine, and the rate of mutation was 1%. The PTEN gene methylation rate of cervical cancer was 62% (63/102) and the rate was associated with the International Federation of Gynecology and Obstetrics stage, cell differentiation, tumor size and lymph node metastasis (P<0.05). The positive rate of PTEN expression was 49% (50/102) in cervical carcinoma and the PTEN expression between stage I‑II and III‑IV [60 (27/45) vs. 40% (23/57)] was statistically significant (P<0.01). The PTEN gene expression between the metastasis and no lymph node metastasis groups [26 (10/38) vs. 63% (40/64)] was significantly different (P<0.01). The PTEN gene promoter methylation and its protein expression had a significant correlation (P=0.042). These results suggest that hypermethylation can inactivate the transcription of PTEN and reduce its protein expression. Downregulated PTEN expression is involved in the pathogenesis, invasion and metastasis of cervical cancer, possibly by regulating the balance between apoptosis and proliferation. Therefore, the PTEN expression may be a good marker for the prognosis of cervical cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
3	Noordhuis MG, Eijsink JJ, Ten HK, et al: Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo) radiation and survival in cervical cancer. Clin Cancer Res. 15:7389–7397. 2009. View Article : Google Scholar : PubMed/NCBI
4	Woelber L, Kress K, Kersten JF, et al: Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer. 11:122011. View Article : Google Scholar : PubMed/NCBI
5	Hellberg D, Tot T and Stendahl U: Pitfalls in immunohistochemical validation of tumor marker expression - exemplified in invasive cancer of the uterine cervix. Gynecol Oncol. 112:235–240. 2009. View Article : Google Scholar : PubMed/NCBI
6	Khunamornpong S, Settakorn J, Sukpan K, et al: Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis. Gynecol Oncol. 112:241–247. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lima EM, Araújo JJ, Harada ML, et al: Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin Exp Med. 5:129–132. 2005. View Article : Google Scholar : PubMed/NCBI
8	Oki E, Kakeji Y, Baba H, et al: Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol. 21:814–818. 2006. View Article : Google Scholar : PubMed/NCBI
9	Stiles BL: Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles. Int J Biochem Cell Biol. 41:757–761. 2009. View Article : Google Scholar : PubMed/NCBI
10	Raftopoulou M, Etienne-Manneville S, Self A, et al: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science. 303:1179–1181. 2004. View Article : Google Scholar : PubMed/NCBI
11	Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
12	Guo CY, Xu XF, Wu JY and Liu SF: PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol. 14:3804–3811. 2008. View Article : Google Scholar : PubMed/NCBI
13	Marsit CJ, Zheng S, Aldape K, et al: PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 36:768–776. 2005. View Article : Google Scholar : PubMed/NCBI
14	Teng Y, Sun AN, Pan XC, et al: Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. Cancer Res. 66:6972–6981. 2006. View Article : Google Scholar : PubMed/NCBI
15	Perrone F, Lampis A, Orsenigo M, et al: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 20:84–90. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kang YH, Lee HS and Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
17	Soria JC, Lee HY, Lee JI, et al: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
18	Yang HJ, Liu VW, Wang Y, et al: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 6:2122006. View Article : Google Scholar : PubMed/NCBI
19	Jiang YA, Fan LF, Jiang CQ, et al: Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J Gastroenterol. 9:491–494. 2003.PubMed/NCBI
20	Schöndorf T, Ebert MP, Hoffmann J, et al: Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett. 207:215–220. 2004.PubMed/NCBI
21	Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
22	Yaginuma Y, Yamashita T, Ishiya T, et al: Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog. 27:110–116. 2000. View Article : Google Scholar : PubMed/NCBI
23	Rizvi MM, Alam MS, Ali A, et al: Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol. 137:1255–1262. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cheung TH, Lo KW, Yim SF, et al: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol. 93:621–627. 2004. View Article : Google Scholar : PubMed/NCBI
25	Wiencke JK, Zheng S, Jelluma N, et al: Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 9:271–279. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
27	Eijsink JJ, Noordhuis MG, ten Hoor KA, et al: The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum Pathol. 41:1735–1741. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lu D, Qian J, Yin X, et al: Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI